shot-button
Ganesh Chaturthi Ganesh Chaturthi
Home > News > India News > Article > Covaxin gets DGCI nod for use in children above 12 years with certain conditions

Covaxin gets DGCI nod for use in children above 12 years with certain conditions

Updated on: 25 December,2021 09:33 PM IST  |  New Delhi
PTI |

The Subject Expert Committee on Covid-19 of the CDSCO on October 12 after deliberating Bharat Biotech's EUA application had recommended granting emergency use approval to Covaxin for use in the 12-18 years age group with certain conditions

Covaxin gets DGCI nod for use in children above 12 years with certain conditions

Photo for representational purpose

The Drugs Controller General of India (DCGI) has granted emergency use authorisation to Bharat Biotech's Covaxin for children above 12 years with certain conditions, sources said on Saturday.


The Subject Expert Committee on Covid-19 of the CDSCO on October 12 after deliberating Bharat Biotech's EUA application had recommended granting emergency use approval to Covaxin for use in the 12-18 years age group with certain conditions.


"The recommendations of the SEC were evaluated by another experts committee after which DCGI had sought additional data from the firm," a source said.


The DCGI gave its approval Friday, the source said.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK